Research programme: Raf inhibitors - SUGEN/ASTA MedicaAlternative Names: Raf inhibitors research programme - SUGEN/ASTA Medica
Latest Information Update: 11 Dec 2002
At a glance
- Originator SUGEN
- Class Small molecules
- Mechanism of Action Raf kinase inhibitors; Ras signal transduction pathway inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 11 Dec 2002 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 06 Apr 2000 Pharmacia & Upjohn has merged with Monsanto to form Pharmacia Corporation
- 21 Sep 1999 SUGEN has been acquired by Pharmacia & Upjohn